{"brief_title": "A Safety and Effectiveness Study of Aroplatin in Patients With Advanced Solid Malignancies", "brief_summary": "To determine the rate of response and the duration of the response following therapy with Aroplatinin patients with advanced solid malignancies.", "detailed_description": "Primary Objective: - Determine response rate (RR; complete and partial response [CR, PR]) and duration after therapy with Aroplatin\u2122 in patients with advanced solid malignancies. Secondary Objective: - Determine the safety and tolerability of Aroplatin", "condition": ["Esophageal Neoplasms", "Hepatocellular Carcinoma", "Colorectal Neoplasms", "Ovarian Neoplasms", "Pancreatic Neoplasms", "Neoplasms"], "intervention_type": ["Drug"], "intervention_name": ["Aroplatin (Liposomal NDDP, L-NDDP)"], "criteria": "Inclusion Criteria: - Advanced solid malignancies; - Amenable to therapy with DACH platinum agents; - Measurable disease (RECIST criteria); - ECOG performance score of 0-2; - Adequate hematopoietic, liver and renal function; - Adequate cardiac function (maximum of class II, NYHA); - Women of childbearing potential must have a negative urine or serum pregnancy test; - Signed written informed consent; - Subjects must be willing to be followed during the course of treatment/observation and follow-up. Exclusion Criteria: - No other active malignancies; - No prior therapy with oxaliplatin; - No known brain metastases; - Active, uncontrolled infection or other serious medical illnesses; - Not using or have used any investigational therapy during four weeks before start of protocol treatment.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "and other solid tumors", "mesh_term": ["Carcinoma", "Neoplasms", "Carcinoma, Hepatocellular", "Colorectal Neoplasms", "Pancreatic Neoplasms", "Ovarian Neoplasms", "Esophageal Neoplasms", "bis-neodecanoato-1,2-diaminocyclohexaneplatinum(II)"], "id": "NCT00057395"}